Table 1.
Demographics of patients with transitional cell carcinoma in different parts of urinary system.
| Characteristic | No. of patients (%) | |||||
|---|---|---|---|---|---|---|
| All patients | Urinary Bladder | Renal Pelvis | Ureter | Urethra | P value | |
| Total no. | 94,187 | 79419 (84.32%) | 8298 (8.81%) | 4138 (4.39%) | 2332 (2.48%) | |
| Age: Mean ± SD | 72.35 ± 10.69 | 72.21 ± 10.74 | 73.10 ± 10.49 | 73.19 ± 9.88 | 72.98 ± 10.99 | <.001 |
| Median age (25th–75th percentile) |
72 (67.5–82) | 72 (67.5–82) | 77.5 (67.5–82) | 77.5 (67.5–82) | 77.5 (67.5–82) | <.001 |
| Age | <.001 | |||||
| <40 | 465 (0.5%) | 401 (0.5%) | 36 (0.4%) | 13 (0.3%) | 15 (0.6%) | |
| 40–49 | 2462 (2.6%) | 2131 (2.7%) | 204 (2.5%) | 73 (1.8%) | 54 (2.3%) | |
| 50–59 | 9856 (10.5%) | 8486 (10.7%) | 780 (9.4%) | 342 (8.3%) | 248 (10.6%) | |
| 60–69 | 21661 (23.0%) | 18525 (23.3%) | 1714 (20.7%) | 942 (22.8%) | 480 (20.6%) | |
| 70–79 | 30122 (32.0%) | 25222 (31.8%) | 2749 (33.1%) | 1455 (35.2%) | 696 (29.8%) | |
| ≥80 | 29621 (31.4%) | 24654 (31.0%) | 2815 (33.9%) | 1313 (31.7%) | 839 (36.0%) | |
| Sex | <.001 | |||||
| Female | 25364 (26.9%) | 19602 (24.7%) | 3583 (43.2%) | 1590 (38.4%) | 589 (25.3%) | |
| Male | 68823 (73.1%) | 59817 (75.3%) | 4715 (56.8%) | 2548 (61.6%) | 1743 (74.7%) | |
| Race | <.001 | |||||
| Hispanic | 5917 (6.3%) | 4839 (6.1%) | 677 (8.2%) | 245 (5.9%) | 156 (6.7%) | |
| White | 77034 (81.8%) | 65323 (82.3%) | 6584 (79.3%) | 3366 (81.3%) | 1761 (75.5%) | |
| Black | 6184 (6.6%) | 5329 (6.7%) | 460 (5.5%) | 177 (4.3%) | 218 (9.3%) | |
| American Indian/Alaskan Asian/Pacific Islander |
4579 (4.9%) | 3528 (4.4%) | 564 (6.8%) | 349 (8.4%) | 138 (5.9%) | |
| Unknown | 473 (0.5%) | 400 (0.5%) | 13 (0.2%) | 1 (<0.001%) | 59 (2.5%) | |
| Marital status | <.001 | |||||
| Married | 53436 (56.7%) | 45165 (56.9%) | 4614 (55.6%) | 2482 (60.0%) | 1175 (50.4%) | |
| SDW | 24748 (26.3%) | 20555 (25.9%) | 2543 (30.6%) | 1147 (27.7%) | 503 (21.6%) | |
| Single | 9541 (10.1%) | 8237 (10.4%) | 764 (9.2%) | 315 (7.6%) | 225 (9.6%) | |
| Unknown | 6462 (6.9%) | 5462 (6.9%) | 377 (4.5%) | 194 (4.7%) | 429 (18.4%) | |
| Median household income | <.001 | |||||
| < $35,000 | 1380 (1.5%) | 1166 (1.5%) | 126 (1.5%) | 60 (1.4%) | 28 (1.2%) | |
| $35,000- $54,999 | 20981 (22.3%) | 17717 (22.3%) | 1804 (21.7%) | 929 (22.5%) | 531 (22.8%) | |
| $55,000- $74,999 | 43347 (46.0%) | 36699 (46.2%) | 3736 (45.0%) | 1825 (44.1%) | 1087 (46.6%) | |
| >$75,000 | 28479 (30.2%) | 23837 (30.0%) | 2632 (31.7%) | 1324 (32.0%) | 686 (29.4%) | |
| Grade | <.001 | |||||
| Grade I | 3140 (3.3%) | 2887 (3.6%) | 134 (1.6%) | 90 (2.2%) | 29 (1.2%) | |
| Grade II | 7656 (8.1%) | 6666 (8.4%) | 566 (6.8%) | 316 (7.6%) | 108 (4.6%) | |
| Grade III | 24515 (26.0%) | 20679 (26.0%) | 2286 (27.5%) | 1156 (27.9%) | 394 (16.9%) | |
| Grade IV | 39742 (42.2%) | 34254 (43.1%) | 2956 (35.6%) | 1742 (42.1%) | 790 (33.9%) | |
| Unknown | 19134 (20.3%) | 14933 (18.8%) | 2356 (28.4%) | 834 (20.2%) | 1011 (43.4%) | |
| SEER Summary stage | <.001 | |||||
| In situ | 15060 (16.0%) | 15060 (19.0%) | NA | NA | NA | |
| Localized | 42664 (45.3%) | 40835 (51.4%) | 1829 (22.0%) | NA | NA | |
| Regional | 16360 (17.4%) | 12856 (16.2%) | 3504 (42.2%) | NA | NA | |
| Distant | 20103 (21.3%) | 10668 (13.4%) | 2965 (35.7%) | NA | NA | |
| Radiotherapy | <.001 | |||||
| No | 86330 (91.7%) | 72346 (91.1%) | 7951 (95.8%) | 3851 (93.1%) | 2182 (93.6%) | |
| Yes | 7857 (8.3%) | 7073 (8.9%) | 347 (4.2%) | 287 (6.9%) | 150 (6.4%) | |
| Chemotherapy | ||||||
| No | 70595 (75.0%) | 59471 (74.9%) | 6165 (74.3%) | 3099 (74.9%) | 1860 (79.8%) | |
| Yes | 23592 (25.0%) | 19948 (25.1%) | 2133 (25.7%) | 1039 (25.1%) | 472 (20.2%) | |
| Surgery recode | <.001 | |||||
| No | 13889 (14.7%) | 9033 (11.4%) | 2640 (31.8%) | 974 (23.5%) | 1242 (53.3%) | |
| Yes | 79804 (84.7%) | 70014 (88.2%) | 5618 (67.7%) | 3144 (76.0%) | 1028 (44.1%) | |
| unknown | 494 (0.5%) | 372 (0.5%) | 40 (0.5%) | 20 (0.5%) | 62 (2.7%) | |
NA = not applicable, SD = standard deviation, SDW = separated, divorced or widowed, SEER = Surveillance, Epidemiology, and End Results program.